Loading...
XHKG9969
Market cap1.14bUSD
Dec 23, Last price  
5.93HKD
1D
0.00%
1Q
10.84%
IPO
-38.99%
Name

InnoCare Pharma Ltd

Chart & Performance

D1W1MN
XHKG:9969 chart
P/E
—
P/S
11.29
EPS
—
Div Yield, %
0.01%
Shrs. gr., 5y
6.39%
Rev. gr., 5y
240.36%
Revenues
739m
+18.09%
102,0001,617,0001,247,0001,364,0001,043,033,000625,404,000738,537,000
Net income
-631m
L-27.58%
-341,734,000-549,950,000-2,138,554,000-463,166,000-66,679,000-871,650,000-631,263,000
CFO
-671m
L+18.70%
-49,356,000-17,677,000-79,753,000-172,519,000167,058,000-565,554,000-671,340,000
Earnings
Jun 27, 2025

Profile

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
URL
https://www.innocarepharma.com/
IPO date
Mar 23, 2020
Employees
939
Domiciled in
CN
Incorporated in
KY

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
738,537
18.09%
625,404
-40.04%
1,043,033
76,368.70%
Cost of revenue
1,137,814
1,272,146
1,131,911
Unusual Expense (Income)
NOPBT
(399,277)
(646,742)
(88,878)
NOPBT Margin
Operating Taxes
1,426
(22,077)
46,558
Tax Rate
NOPAT
(400,703)
(624,665)
(135,436)
Net income
(631,263)
-27.58%
(871,650)
1,207.23%
(66,679)
-85.60%
Dividends
(1,153)
(3,263)
Dividend yield
0.01%
0.02%
Proceeds from repurchase of equity
3,647
2,923,230
2,527,459
BB yield
-0.03%
-14.48%
-12.09%
Debt
Debt current
1,274,364
1,217,280
20,336
Long-term debt
136,827
90,990
1,315,784
Deferred revenue
278,203
123,611
Other long-term liabilities
574,483
287,761
37,693
Net debt
(6,819,065)
(7,401,369)
(4,918,694)
Cash flow
Cash from operating activities
(671,340)
(565,554)
167,058
CAPEX
(254,544)
(370,327)
(167,069)
Cash from investing activities
666,914
(1,726,354)
(1,729,965)
Cash from financing activities
1,308
3,094,506
2,544,807
FCF
(537,529)
(1,074,512)
(283,476)
Balance
Cash
8,224,596
9,011,217
6,245,775
Long term investments
5,660
(301,578)
9,039
Excess cash
8,193,329
8,678,369
6,202,662
Stockholders' equity
(5,021,311)
(4,375,679)
(3,481,956)
Invested Capital
14,120,810
13,806,109
10,533,161
ROIC
ROCE
EV
Common stock shares outstanding
1,706,116
1,479,565
1,366,261
Price
6.89
-49.49%
13.64
-10.85%
15.30
13.00%
Market cap
11,755,139
-41.75%
20,181,267
-3.46%
20,903,793
59.56%
EV
4,968,930
12,863,435
16,270,310
EBITDA
(306,656)
(578,339)
(56,396)
EV/EBITDA
Interest
35,031
17,045
2,642
Interest/NOPBT